Statistics show that obstructive sleep apnea (OSA) is a common disorder affecting around 30 million adults in the US. In a recent press release, the American Food and Drug Administration has approved the first ever prescription medicine to tackle this condition.
Zepbound (tirzepatide), a weight-loss drug, has now been approved by medical experts to effectively improve OSA by reducing appetite and food intake. This is because it was observed that while anyone can be affected by it, OSA is more prevalent in people who are obese or overweight. The decision was made based on the results of two clinical trials on 469 adults on whom the drug was administered for 52 weeks.
